Best Warren Buffett Stocks To Buy For 2014

Strength in telecom stocks was apparent during Thursday�� trading even before the news that Warren Buffett had established a major position in Verizon.

These 3 telecoms had already made the list of new 52-week highs prior to the disclosure that the Omaha oracle picked up half a billion dollars worth of Verizon:

1. Windstream Windstream Corporation (NYSE:WIN) With a price-earnings ratio of 25, it would be hard to call this a value stock. Part of the attraction of VZ for Buffett is that low p/e of 10. Windstream is paying a 10% dividend while sitting on a great deal of debt. Some analysts have wondered if that level of dividend payment can be sustained. The stock price has galloped from 7 in February to 9.5 in May. That�� quite an uptrend in a short period of time.

2. CenturyLink CenturyLink (NYSE:CTL) This is another telecom that�� been moving upward a lot lately ��from 27 to 37 in the last 4 months. Because the company did not earn money last year, there is no price/earnings ratio. Last I checked, the 5.7% dividend was still being paid.

Top Supermarket Companies To Buy For 2015: Conatus Pharmaceuticals Inc (CNAT)

Conatus Pharmaceuticals Inc., incorporated on July 13, 2005, is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. The Company has designed a clinical program to demonstrate the therapeutic benefit of emricasan across the spectrum of fibrotic liver disease. The Company�� initial development strategy targets indications for emricasan with high unmet clinical need in orphan patient populations, such as patients with acute-on-chronic liver failure (ACLF), chronic liver failure (CLF), and patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT).

The Company has completed two placebo-controlled Phase II trials in patients with liver disease showing reductions in ALT levels that occur rapidly, within as little as one day after initiation of therapy, and are maintained throughout the treatment period. In the Company�� 204-patient Phase 2b trial, it also measured cCK18, an important biomarker of apoptosis and disease severity. Emricasan has been generally well-tolerated in all of the clinical studies. As of July 23, 2013, the Company had not generated any revenue.

Advisors' Opinion:

• [By John Udovich]

  While Intercept Pharmaceuticals Inc (NASDAQ: ICPT) surged earlier this year and Achillion Pharmaceuticals, Inc (NASDAQ: ACHN) has surged this week after Merck & Co. Inc (NYSE: MRK) agreed to purchase hepatitis stock�Idenix Pharmaceuticals Inc (NASDAQ: IDIX) at a 239% premium, it seems the herd has realized that small cap Conatus Pharmaceuticals Inc (NASDAQ: CNAT) is also a liver disease stock as shares suddenly surged 56.69% on no apparent company news. But just what is�Conatus Pharmaceuticals and is it worth taking a chance on?

• [By Lauren Pollock]

  Conatus Pharmaceuticals Inc.'s(CNAT) shares jumped 26% to $7.75 premarket after the biotechnology firm said its treatment for chronic liver disease has been granted a status that could mean quicker approval.

Best Warren Buffett Stocks To Buy For 2014: Baytex Energy Corp (BTE)

Baytex Energy Corp. (Baytex), incorporated on October 22, 2010, through its subsidiaries, are engaged in the business of acquiring, developing, exploiting and holding interests in petroleum and natural gas properties and related assets in Canada (in the provinces of British Columbia, Alberta and Saskatchewan) and in the United States (in the states of North Dakota and Wyoming). The Company acts as the financing vehicle for its subsidiaries by providing access to debt and equity capital markets. As of December 31, 2011, its primary assets are Baytex Energy Ltd. (Baytex Energy), which it owns. On February 3, 2011, the Company acquired heavy oil assets located in the Reno area of northern Alberta and the Lloydminster area of western Saskatchewan. On August 9, 2011, the Company acquired natural gas assets located in the Brewster area of west central Alberta. During the year ended December 31, 2011, it completed two dispositions of undeveloped lands; in the Kaybob South area of west central Alberta, it sold six sections of leasehold, including five sections with Duvernay rights, and in the Dodsland area in southwest Saskatchewan, it sold 32,600 net acres of leasehold in the halo of the field.

During 2011, the Company�� production averaged 50,132 barrel of oil equivalent per day, from its properties in Canada. During 2011, production averaged 50,132 barrel of oil equivalent per day. During 2011, light oil and natural gas liquid (NGL) production was 6,769 barrels per day. During 2011, heavy oil production was 35,252 barrels per day. During 2011, natural gas production was 48.7 million cubic feet per day. Its crude oil and natural gas operations are organized into three business units: Alberta/B.C., Saskatchewan and United States. Each business unit has a portfolio of mineral leases, operated and non-operated properties and development prospects. These plays include the Bakken/Three Forks in the Williston Basin of North Dakota and southeast Saskatchewan and the Viking in southwestern Saskatche! wan and eastern Alberta.

Saskatchewan Business Unit

As of December 31, 2011, the Saskatchewan Business Unit accounted for more than 38% of production. The Saskatchewan Business Unit's heavy oil operations include cold primary and thermal (steam-assisted gravity drainage) production. Production is generated from vertical, slant and horizontal wells using progressive cavity pumps capable of handling heavy oil combined with gas, water and sand. Once produced, the oil is delivered to markets in both Canada and the United States on pipelines, tanker trucks or railways. Heavy crude is blended with light-hydrocarbon diluents (such as condensate) prior to being introduced into a sales pipeline. The blended crude oil is then sold by Baytex. During 2011, production in the Saskatchewan Business Unit averaged approximately 20,958 barrels of oil equivalent per day, which was comprised of 19,828 barrels per day of heavy oil, 154 barrels per day of light oil and 5,860 thousand cubic feet per day of natural gas. During 2011, Baytex drilled 93 (87.9 net) wells in the Saskatchewan Business Unit resulting in 84 (78.9 net) oil wells, four stratigraphic test wells, four service wells, and one dry and abandoned well.

The Company�� Ardmore, Alberta is developed in the Sparky, McLaren and Colony formations. During 2011, average production was approximately 652 barrels per day of heavy oil and 158 thousand cubic feet per day of natural gas. During 2011, one well was drilled. As of December 31, 2011, Baytex had 34,000 net undeveloped acres in this area. Its Carruthers property consists of separate North and South oil pools in the Cummings formation. During 2011, 13 wells were drilled. During 2011, average production was approximately 2,444 barrels per day of heavy oil and 489 thousand cubic feet per day of natural gas. As of December 31, 2011, Baytex had 10,600 net undeveloped acres in this area. During 2011, the Company�� Celtic, Saskatchewan producing property produced averaged 3,013 ! barrels p! er day of heavy oil and 538 thousand cubic feet per day of natural gas. During 2011, Baytex drilled seven oil wells in the area. The Company�� Cold Lake, Alberta is a heavy oil property. Production is from the Colony, Upper McLaren, Rex and Sparky formations. During 2011, average oil production was approximately 270 barrels per day. During 2011, Baytex had 11,300 net undeveloped acres in this area.

During 2011, in Kerrobert SAGD project, the Company placed two new well pairs on production. During 2011, average production from the Kerrobert area was approximately 3,350 barrels per day of heavy oil, 154 barrels per day of light oil, and 1,999 thousand cubic feet per day of natural gas. During 2011, Baytex drilled five oil wells and eight service wells in this area. As of December 31, 2011, Baytex had 38,600 net undeveloped acres in this area. Lindbergh is a non-operated heavy oil property. Baytex has a 21.25% working interest in this property. During 2011, average production in this area was approximately 673 barrels per day of heavy oil and 71 thousand cubic feet per day of natural gas. During 2011, four wells were drilled in this area. As of December 31, 2011, Baytex had 800 net undeveloped acres in this area. During 2011, its Marsden/Epping/Macklin/Silverdale, Saskatchewan produced approximately 2,102 barrels per day of oil and 290 thousand cubic feet per day of natural gas. During 2011, nine oil wells were drilled in this area. Its Tangleflags is characterized by multiple-zone reservoirs with production from the Colony, McLaren, Waseca, Sparky, General Petroleum and Lloydminster formations. During 2011, Baytex drilled 11 horizontal oil wells in the Lloydminster formation. During 2011, average production was approximately 1,763 barrels per day of heavy oil and 543 thousand cubic feet per day of natural gas.

Alberta/B.C. Business Unit

The Alberta/B.C. Business Unit possesses a range of light oil, heavy oil and natural gas properties. During 2011, the Alberta/B.C.! Business! Unit produced light and heavy gravity crude oil, natural gas, and natural gas liquids from fields in Alberta and British Columbia and accounted for approximately 58% of production. During 2011, production from this business unit averaged 27,833 barrel of oil equivalent per day, which was comprised of 15,425 barrels per day of heavy oil, 5,282 barrels per day of light oil and NGL and 42.8 million cubic feet per day of natural gas. During 2011, the Alberta/B.C. Business Unit participated in the drilling of 71 wells resulting in 61 oil wells, one natural gas well, seven stratigraphic test wells, one service well and one dry and abandoned well. As of December 31, 2011, its net undeveloped lands in this business unit totaled approximately 474,000 acres. During 2011, production from Bon Accord area was averaged approximately 905 barrels per day of light oil and 1,742 million cubic feet per day of natural gas. Natural gas is processed at two Baytex-operated plants and oil is treated at three Baytex-operated batteries. During 2011, in this area, Baytex drilled 11 horizontal Viking oil wells. As of December 31, 2011, Baytex had 18,300 net undeveloped acres in this area.

The Company�� Darwin/Nina/Goodfish/Lafond, Alberta produces natural gas from the Bluesky formation. During 2011, production averaged approximately 3,746 million cubic feet per day of natural gas. As of December 31, 2011, Baytex had 27,300 net undeveloped acres in this area. During 2011, the Company�� Leahurst, Alberta produced averaged approximately 2,633 million cubic feet per day of natural gas and 13 barrels per day of NGL from this multi-zone, year-round access area. Natural gas production from the Edmonton, Belly River, Viking and Mannville formations is processed. Baytex holds a total of 263 net sections of oil sands leases in the Peace River oil sands area, which includes the legacy Seal area and the Reno area. During 2011, production from the Peace River area was 15,425 barrels per day, which was comprised of 13,746 barr! els per d! ay from Seal and 1,679 barrels per day from Reno. During 2011, Baytex drilled 25 cold horizontal production wells and seven stratigraphic test wells at Seal and two cold horizontal production wells at Reno. The Peace River area includes 152,500 net undeveloped acres, including 57,000 net undeveloped acres at Seal and 95,500 net undeveloped acres at Reno.

During 2011, the Company�� Pembina production averaged 2,633 barrels per day of light oil and NGL and 22,428 million cubic feet per day of natural gas. During 2011, Baytex participated in drilling 19 wells in this area, resulting in 17 oil wells, one natural gas well, and one dry and abandoned well. During 2011, Pembina area drilling included five operated and 12 non-operated Cardium horizontal wells and completed with multi-stage fracture stimulations. During 2011, the Company�� production from Red Earth area averaged approximately 42 million cubic feet per day of natural gas and 522 barrels per day of light oil and NGL. During 2011, the Company�� Richdale/Sedalia property�� production averaged approximately 3,845 million cubic feet per day of natural gas and eight barrels per day of NGL. During 2011, the Company�� production from Stoddart area averaged approximately 4,498 million cubic feet per day of natural gas and 713 barrels per day of oil and NGL. During 2011, production from Turin was averaged approximately 345 barrels per day of oil and NGL and 856 million cubic feet per day of natural gas. Production is from the Second White Specks, Milk River, Bow Island, Mannville, Sawtooth and Livingstone formations.

United States Business Unit

During 2011, the Company focused its activities on the light oil resource play located in the Divide and Williams Counties of North Dakota. Production is from horizontal wells using multi-stage hydraulic fracturing in the Bakken and Three Forks formations. As of December 31, 2011, Baytex owned approximately 61,000 (24,800 net) developed acres. During 2011, Baytex parti! cipated i! n the drilling of 34 Bakken/Three Forks oil wells. During 2011, net production from the United States properties averaged 1,341 barrels of oil equivalent per day.

Advisors' Opinion:

• [By Rich Duprey]

  Canadian oil and gas producer�Baytex Energy (NYSE: BTE  ) announced yesterday its monthly dividend payment for June of $0.22 Canadian per share, the same monthly rate it's paid since 2011.�The U.S. dollar equivalent is approximately $0.2162 per share, assuming a foreign exchange rate of $0.9826 USD-CAD.

• [By Robert Rapier]

  There are a number of quality Canadian E&P companies that are attractive at current prices. Among my favorites are Baytex Energy (NYSE: BTE, TSE: BTE), Cenovus Energy (NYSE: CVE, TSE: CVE) and Canadian Natural Resources (NYSE: CNQ, TSE: CNQ) I also like Peyto Exploration & Development (TSE: PEY, OTC: PEYUF) for aggressive investors. We have often discussed putting Peyto in one of the portfolios, but I would ideally like it a bit cheaper.

• [By Ari Charney]

  Baytex Energy Corp (TSX: BTE, NYSE: BTE) is among the heavy crude-oriented E&Ps to which the firm recommends increased exposure.

  Although Baytex has risen 9.8 percent over the trailing 12-month period, the stock is down about 14 percent from its mid-June high. Nevertheless, analyst sentiment remains firmly bullish, at 18 ��uys,��three ��olds,��and one ��ell.��/p>

• [By Stephan Dube]

  Peace River's most notable producers:

  PennWest Exploration (PWE), see article here.Royal Dutch Shell (RDS.A), see article here.Baytex (BTE), see article here.Strata Oil and Gas (SOIGF.PK), see article here.Petrobank Energy & Resources (PBEGF.PK), see article here.

  Cold Lake's most notable producers:

Best Warren Buffett Stocks To Buy For 2014: Groupe Eurotunnel SA (GET)

Groupe Eurotunnel SA, (also GET SA), is a France-based company having its expertise in infrastructure management and railway operations. It manages and operates the Channel Tunnel between the United Kingdom and France and its railway infrastructure. The Company is also engaged in passenger and freight transport between continental Europe and the United Kingdom. In addition, it provides ferry transport through the Channel. Groupe Eurotunnel SA has direct and indirect stakes in a number of companies, including The Channel Tunnel Group Limited, France Manche SA, Europorte SAS, Europorte Channel SAS, Europorte Proximite SAS, GB Railfreight Limited, Eurotunelplus GmbH and others. Advisors' Opinion:

• [By Robert Wall]

  At the same time it faces new competition as Deutsche Bahn plans services from Germany to London via the Channel Tunnel from 2016 after a three-year safety study, Groupe Eurotunnel SA (GET), which runs the 30-mile subsea link, said in June.

Best Warren Buffett Stocks To Buy For 2014: Mid-America Apartment Communities Inc (MAA)

Mid-America Apartment Communities, Inc., incorporated on September 22, 1993, is a self-administered and self-managed real estate investment trust (REIT). The Company focuses on acquiring, owning and operating apartment communities in the Sunbelt region of the United States. The Company�� segments include Large market same store communities , Secondary market same store communities and Non same store communities and other . As of December 31, 2012 , the Company owned 100% of 160 properties representing 47,809 apartment units. Four properties include retail components with approximately 108,000 square feet of gross leasable area.

As of December 31, 2012 , the Company also had 33.33% ownership interests in Mid-America Multifamily Fund I, LLC, or Fund I, and Mid-America Multifamily Fund II, LLC, or Fund II, which owned two properties containing 626 apartment units and four properties containing 1,156 apartment units, respectively. These apartment communities were located across 13 states. In October 2013, Mid-America Apartment Communities Inc merged with Colonial Properties Trust. In October 2013, Mid America Apartment Communities Inc and Colonial Properties Trust announced the completion of the merger of the two companies.

The Company�� Large market same store communities are generally communities in markets with a population of at least one million and at least 1% of the total public multifamily REIT units that the Company has owned and that has been stabilized for at least a full 12 months and have not been classified as held for sale. Communities are considered stabilized after achieving and maintaining at least 90% occupancy for 90 days. Secondary market same store communities are generally communities in markets with populations of more than one million but less than 1% of the total public multifamily REIT units or markets with populations of less than one million that the Company has owned and that has been stabilized for at least a full 12 months and have not been cl! assified as held for sale. Communities are considered stabilized after achieving and maintaining at least 90% occupancy for 90 days. Non same store communities and other includes recent acquisitions, communities in development or lease-up and communities that have been classified as held for sale. Also included in non same store communities are non multifamily activities which represent less than 1% of the Company's portfolio.

The Company's business is conducted principally through Mid-America Apartments, L.P., which the Company refers to as its Operating Partnership. As of December 31, 2012 , the Company owned or had an ownership interest in 166 multifamily apartment communities in 13 different states. The Company also provides its own in-house leadership development program, which consists of a three-module program followed by two comprehensive case studies, which was developed with the assistance of U.S. Learning, Inc. During the year ended December 31, 2012, the Company purchased 10.6 acres of land and began construction on a new 270-unit community located in the Charleston, South Carolina metropolitan area. As of December 31, 2012 , no units have been delivered for the land in Charleston, South Carolina. During 2012, the Company also purchased 2.0 acres of land and began construction on a new 294-unit community located in Jacksonville, Florida.

Advisors' Opinion:

• [By Rich Duprey]

  Apartment-only real estate investment trust�Mid-America Apartment Communities� (NYSE: MAA  ) once again is snapping up properties, this time announcing Monday that it is adding�multifamily housing operator Colonial Properties Trust (NYSE: CLP  ) to its portfolio in an $8.6 billion transaction.�

• [By Sean Williams]

  Living in a renter's paradise
  The last quarter has been rough on housing and office space real estate investment trusts, with 30-year mortgage rates spiking from less than 3.5% to as high as 4.75% recently. Low lending rates were one of the keys fueling the housing rally higher, so higher lending rates stemming from the potential wind-down of QE3 could serve to stymie growth. Yet for residential-REITs like Mid-America Apartment Communities (NYSE: MAA  ) , the effect would actually be extremely positive.

• [By Marc Bastow]

  Apartment community property real estate investment trust Mid-America Apartment Communities (MAA) raised its quarterly dividend 5% to 73 cents per share, payable on Jan. 31 to shareholders of record as of Jan. 15.
  MAA Dividend Yield: 4.69%

• [By Rich Duprey]

  Apartment-only real estate investment trust Mid-America Apartment Communities (NYSE: MAA  ) added yet another multi-family housing community to its portfolio, announcing yesterday it had�completed the acquisition of Station Square at Cosner's Corner, a 260-unit upscale multi-family apartment community located in�Fredericksburg, Va.

Best Warren Buffett Stocks To Buy For 2014: McDonald's Corporation(MCD)

McDonald?s Corporation, together with its subsidiaries, operates as a worldwide foodservice retailer. It franchises and operates McDonald?s restaurants that offer various food items, soft drinks, coffee, and other beverages. As of December 31, 2009, the company operated 32,478 restaurants in 117 countries, of which 26,216 were operated by franchisees; and 6,262 were operated by the company. McDonald?s Corporation was founded in 1948 and is based in Oak Brook, Illinois.

Advisors' Opinion:

• [By Jim Jubak]

  Energy stocks, well, I don�� see oil moving up a whole lot. It doesn�� look like it is going to be necessarily a bad time for energy stocks because oil is going to be dropping, but I don�� see a whole lot of energy in the sector. But the real problem, I think, is consumer stocks. These are kind of like the safe stocks that people go to when they want to be in the market but they��e a little worried about the market. You know the stocks I mean, McDonald�� (MCD), Coca-Cola (KO), Pepsi (PEP), the companies that have theoretically steadily growing earnings. The problem is we��e had a lot of bad news from those stocks in the fourth quarter and in, sort of, month-to-month figures from companies like McDonald�� for January and February that we��e not seeing much in the way of growth. Two problems there, one of which is sort of general, which is that we��e not seeing a whole lot of increases in growth, sort of acceleration in the growth rate in emerging markets. In fact, we have seen a deceleration, and that has had an effect on companies like McDonald��. The other is that we��e battling some individual, or sector trends, so that McDonald��, for example, is fighting against a lot more competition, in the sense that, for some percentage of the market, they are really not very exciting anymore as destination restaurants. For Coke and Pepsi, we��e dealing with the fact that cola drinks and sweetened fizzy drinks, in general, are sort of losing market share, again, losing some pizzazz. If you look at all of these sectors and say, ��kay, so what�� going to drive the market higher from here,��a lot of the sectors that were doing the job in January, and the first half of February, seem to have run out of gas, and that may leave us with very little, other than technology, and it�� hard to see technology being sufficient in and of itself to drive the market from here and that is what I �� look for in the week ahead, what�� our leaders

Best Warren Buffett Stocks To Buy For 2014: AstraZeneca PLC (AZN)

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�� products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. On August 31, 2011, the Company completed the sale of the Astra Tech business to DENTSPLY International Inc. On June 19, 2012, the Company acquired Ardea Biosciences Inc (Ardea), a biotechnology company in San Diego, California. In July 2012, the Company acquired a portfolio of neuroscience assets from Link Medicine Corporation. In August 2012, Alliance Pharma plc�� wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands Paludrine, Avloclor and Savarine from AstraZeneca UK Limited. In August 2012, the Company and Bristol-Myers Squibb Company announced the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb Company. In June 2013, the Company acquired Pearl Therapeutics.

Cardiovascular

The Company�� marketed products include Crestor (rosuvastatin calcium), Atacand2 (candesartan cilexetil), Seloken/Toprol-XL (metoprolol succinate), Tenormin (atenolol), Plendil (felodipine), Zestril3 (lisinopril dihydrate), Brilinta/Brilique (ticagrelor), and Axanum, (acetylsalicylic acid (ASA). Crestor1 is a statin used for the treatment of dyslipidaemia and hypercholesterolemia. In some markets, it is also indicated to slow the progression of atherosclerosis and to re! duce the risk of first cardiovascular (CV) events. Atacand2 is an angiotensin II antagonist used for the 1st line treatment of hypertension and symptomatic heart failure. Seloken/Toprol-XL is a beta-blocker once-daily tablet used for 24-hour control of hypertension and for use in heart failure and angina.

Tenormin is a cardioselective beta-blocker used for hypertension, angina pectoris and other CV disorders. Plendil is a calcium antagonist used for the treatment of hypertension and angina. Zestril3 is an angiotensin-converting enzyme inhibitor used for the treatment of a wide range of CV diseases, including hypertension. Brilinta/Brilique is an oral antiplatelet for the treatment of acute coronary syndromes (ACS). Axanum is a fixed dose combination indicated for prevention of CV events in high-risk CV patients in need of daily low-dose ASA treatment and who are at risk of gastric ulcers.

The Company�� marketed products for diabetes include Komboglyze ((saxagliptin and metformin HCl), Kombiglyze XR (saxagliptin and metformin XR) and Onglyza (saxagliptin). Komboglyze is an immediate release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with Type 2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets. Kombiglyze XR is an extended release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. Onglyza is a DPP-IV inhibitor used for the treatment of Type 2 diabetes.

Gastrointestinal

AstraZeneca�� marketed products include Nexium (esomeprazole), Losec/Prilosec (omeprazole) and Entocort (budesonide). Nexium is a proton pump inhibitor (PPI) used for the treatment of acid-related diseases to offer clini! cal impro! vements over other PPIs and other treatments. Losec/Prilosec is used for the short-term and long-term treatment of acid-related diseases. Entocort is a corticosteroid used for the treatment of inflammatory bowel disease. Nexium is marketed in approximately 120 countries and is available in oral (tablet/capsules and oral suspension) and intravenous (i.v.) dosage forms for the treatment of acid-related diseases.

Infection

The Company�� marketed products include Merrem/Meronem (meropenem), Cubicin (daptomycin) and FluMist/Fluenz (influenza vaccine live, intranasal). Merrem/Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalised patients. Cubicin is a cyclic lipopeptide anti-bacterial used for the treatment of serious infections in hospitalised patients. FluMist/Fluenz is an intranasal live, attenuated, trivalent influenza vaccine.

Neuroscience

AstraZeneca�� marketed products include Seroquel IR (quetiapine fumarate), Seroquel XR (an extended release formulation of quetiapine fumarate), Zomig (zolmitriptan), Diprivan (propofol), Vimovo (naproxen/esomeprazole magnesium), Naropin (ropivacaine), Xylocaine (lidocaine) and EMLA (lidocaine and prilocaine). Seroquel IR is an atypical anti-psychotic drug used for the treatment of schizophrenia and bipolar disorder (mania, depression and maintenance). Seroquel XR is used for the treatment of schizophrenia, bipolar disorder, MDD and in some territories for generalised anxiety disorder (GAD).

Zomig is used for the treatment of migraines with or without aura and Zomig Nasal Spray is indicated for the acute treatment of cluster. Diprivan is an intravenous general anaesthetic used in the induction and maintenance of general anaesthesia, for use in intensive care sedation and conscious sedation for surgical as well as diagnostic procedures. Vimovo is a fixed-dose combination of enteric-coated naproxen (an NSAID) with the gastroprotection of immediate release ! esomepraz! ole (a proton pump inhibitor) for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the developing of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Naropin is used as a long-acting local anaesthetic, for surgical anaesthesia and acute pain management. Xylocaine is a used short-acting local anaesthetic. EMLA is used as a local anaesthetic for topical application.

Oncology

AstraZeneca�� marketed products include Arimidex (anastrozole), Zoladex (goserelin acetate implant), Casodex (bicalutamide), Iressa (gefitinib), Faslodex (fulvestrant), Nolvadex (tamoxifen citrate) and Caprelsa (vandetanib). Arimidex is an aromatase inhibitor used for the treatment of early breast cancer. Zoladex, in one- and three-month depots, is a luteinising hormone-releasing hormone agonist used for the treatment of prostate cancer, breast cancer and certain benign gynaecological disorders. Casodex is an anti-androgen therapy used for the treatment of prostate cancer.

Advisors' Opinion:

• [By Maynard Paton]

  LONDON -- The shares of�AstraZeneca� (LSE: AZN  ) (NYSE: AZN  ) added 50 pence to 3,479 pence during early London trading this morning after the company announced the purchase of�Omthera Pharmaceuticals� (NASDAQ: OMTH  ) .

• [By MONEYMORNING.COM]

  For instance, as I wrote this, Pfizer Inc. (NYSE: PFE) was still pursuing a $100 billion-plus merger with AstraZeneca PLC (NYSE ADR: AZN).

  The recent retreat of biotech stocks from a blistering two-year rally really wasn't about fundamentals.

Best Warren Buffett Stocks To Buy For 2014: Sector SPDR Trust SBI Interest (XLK)

Sector SPDR Trust SBI Interest, formerly Technology Select Sector SPDR Fund, seeks to provide investment results that correspond to the price and yield performance of the Technology Select Sector of the S&P 500 Index (the Index). The Index includes companies primarily involved in industries, such as information technology (IT) consulting, semiconductor equipment and products, computers and peripherals, diversified telecommunication services and wireless telecommunication services.

It utilizes a passive or indexing investment approach to invest in a portfolio of stocks that seek to replicate the Index. Sector SPDR Trust SBI Interest's investment advisor is SSgA Funds Management, Inc.

Advisors' Opinion:

• [By Joseph Hogue]

  At the height of the fiscal cliff scare, there were few places investors could hide. Every single sector saw losses. The Technology Select Sector SPDR (NYSE: XLK) dropped more than 12.5%, and even the Health Care Select Sector SPDR (NYSE: XLV) booked losses of 2.6% over the period.